Rhythm Pharmaceuticals revealed that CEO David Meeker and CFO Hunter Smith will participate in fireside chats at major investor conferences in Boston and New York during August and September 2026. These events provide the company an opportunity to discuss its commercial-stage biopharmaceutical developments, including its lead product IMCIVREE® for rare neuroendocrine diseases. The sessions will be webcast and available on Rhythm's website, allowing investors to gain insights into the company's progress and future plans. This engagement highlights Rhythm's efforts to maintain transparency and investor relations as it advances its clinical programs and market presence.
Berlin's state government refused to pay a 30 Bitcoin ransom (about $2.4 million) demanded by the Rhysida ransomware group, leading to the release of 5.7 terabytes of stolen data on the dark web. The cyberattack, detected on August 14, disrupted two ...
Bitcoin traded near $79,972, up 0.43% in 24 hours, with optimism for reaching $85,000 fueled by strong ETF inflows and bullish market sentiment. The global crypto market cap rose to $2.72 trillion, led by gains in Solana, Ethereum, XRP, and BNB. Key ...
OPEC+ decided to keep its oil production unchanged for October, awaiting a full review of member capacities before setting new 2027 quotas. The ongoing Iran war disrupts exports through the Strait of Hormuz, limiting OPEC+'s ability to meet productio...
On September 3, 2026, XRP Healthcare wallets were hacked, resulting in the theft of approximately 267,000 XRP and millions of related tokens. The breach exploited a critical security flaw involving users' private seed phrases, which were exposed when...
Dogecoin has surged past its 200-day moving average, approaching the key $0.10 resistance level after a strong rally from around $0.08. This breakout strengthens its short-term bullish outlook, with technical patterns suggesting potential further gai...
